Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It would be better for all if you were to list them rather than guessing.
I’m going to be specific:
Please keep your posting to facts about your investment, your HONEST questions, & your research.
Please quit this attacking each other based on calling each other names and other such childish behavior. Many of you are acting like MORONS, not investors!
Please quit this attacking EDEX by name calling, including the word SCAM and LIAR.
Posting regarding facts both positive and negative have always been welcome and have never been removed. Name calling is just that and will be removed.
The rest of the garbage posting that has been happening will be more frequently deleted.
Use your energy in a more positive way, do some homework, do your own DD, and stick to the issues.
Mod.
A pump and dump scam????
Really?????
OMG, I could list a hundred P&D scams, but this is not one.
They may not have a producing well, but that is not the result of not trying.
A well missed due to poor porosity does not make a scam. It makes a dry hole. And that is what it makes.
Investors who lost $ on that hole does not make a scam. It makes a loss. That includes EDEX and its investors.
If they were to have his a big well, would you still call it a scam??? I don't think so. And there is the difference.
Sour grapes doesn't make it a scam.
Want a scam?
How about no financials filed?
How about no return of emails?
How about a director who cannot be contacted in any way?
How about a mailbox at a UPS store and nothing else?
How about a trillion shares dumped with fake PR's and nothing real behind it? Then a reverse spit - This repeated yearly for many years.
How about PR's that say we are drilling when we are not?
How about PR's touting multi million dollar contracts that are bogus?
Should I go on and on as to what a scam is?
EDEX has NOT produced a producing well, and that is bad for its investors, but it in NOT a scam.
Energy...
Please consider doing your own DD. & please spare us the emotional energy and deflection of the issue by saying you can't do any DD.
Go back and read this board from the beginning. Your question will be answered as you actually do some work of research on your own. Do your own DD instead of someone else doing it for you.
You Wrote:
"I do DD,otherwise I'd just buy a lottery ticket!Go ahead and blame the investors,if you must,but I think everyone has been misled,lied too,and scammed."
Ok, you say you do DD. Please tell me and the board about the last 15 wells drilled by GeoSurveys.
Please name them and give the results.
Waiting.......
2ndly, if you actually do DD, then you were NOT lied to, misled and scammed. You invested according to your DD as you claim.
You're statement is contradictory. Rather than blame others, take responsibility for your own decisions and so called DD.
Why we won WW2
Look at this cartoon from 1934 and look especially carefully at the plan of action. Remember the adage, "Those who do not remember the past are doomed to repeat it" Looks like we could be in for difficult times. Frightening.
Chicago Tribune cartoon 1934.
The question: What has changed?
(1 Tim 5:8 NIV) If anyone does not provide for his relatives, and especially for his immediate family, he has denied the faith and is worse than an unbeliever.
This should really bother jagman. I both posted and posted a bible verse. ;)
Clueless ye be.......
A much better post!
IMO, Tom is more than legal to discuss issues on this board just as he is able to talk to shareholders on the phone.
Any release of results of this present drill should be over an official PR. I would agree that this kind of information should be delivered as such.
Tom, we look forward to the start, finish and the results.
May this be the first of many black gold announcements.
Top Hat
Easter is Cancelled. Sorry, it was an accident.
Absolutely, the results have ALWAYS been the same.
If attention is paid to William Bradford's journal (dating back to the voyage on the Mayflower,) the Pilgrims had the same goal (communal living, share and share alike), the same outcome (no one would put forth effort) and the same change to accomplish survival (a turn to a capitalistic society).
It was, as Bradford journals, that when each was given his own plot of land to produce, that effort and success was achieved.
One can research for themselves if interested the story of William Bradford, the journey on the Mayflower, the compact, the result and the recordings of Bradford that brought the changes that resulted in survival.
It actually is a heart of man issue. And that my friend has never changed! We are all broken and in need of a Savior.
How come the liberal press is not DEMANDING the serial numbers off the weapons being used by the Mexican cartel?
Could it be because they can be traced to the Mexican army? thusly removing their agenda argument???
Nope, didn't forget. You haven't seen me post on this board or anything about EDEX since the new year.
I did post about Dragon Man and I couldn't help last nights post.
You HAVEN'T seen me post about EDEX, though I am still long and for good reason.
As far as a TOU issue you proffered...... get your head out of... An agreement is quite different and no TOU issue.
Like I said, I haven't said a word about EDEX since the new year. However, Should I decide to post, it's not a TOU violation and there is nothing you can do about it. You can whine and moan all you want, and I expect it, but that all you can do. As most of your many posts indicate, you are very good at that.
Well said. :)
6kidz: its spelled "Archaeology", or even "Archeology"
Alcohol and emotions involved? Guess so...
THE LAW IS THE LAW
So "if" the US government determines that it is against the law for the words "under God" to be on our money, then, so be it.
And "if" that same government decides that the "Ten Commandments" are not to be used in or on a government installation, then, so be it.
I say, "so be it," because I would like to be a law abiding US citizen.
I say, "so be it," because I would like to think that smarter people than I are in positions to make good decisions.
I would like to think that those people have the American public's best interests at heart.
BUT, YOU KNOW WHAT ELSE I'D LIKE?
Since we can't pray to God, can't "Trust in God" and cannot post His Commandments in Government buildings, I don't believe the Government and it's employees should participate in the Easter and Christmas celebrations which honor the God that our government is eliminating from many facets of American life.
I'd like my mail delivered on Christmas, Good Friday, Thanksgiving & Easter. After all, it's just another day.
I'd like the US Supreme Court to be in session on Christmas, Good Friday, Thanksgiving & Easter as well as Sundays. After all, it's just another day.
I'd like the Senate and the House of Representatives to not have to worry about getting home for the "Christmas Break." After all it's just another day.
I'm thinking that a lot of my taxpayer dollars could be saved, if all government offices & services would work on Christmas, Good Friday & Easter. It shouldn't cost any overtime since those would be just like any other day of the week to a government that is trying to be "politically correct."
In fact....
I think that our government should work on Sundays initially set aside for worshipping God... because, after all, our government says that it should be just another day....
What do you all think????
If this idea gets to enough people, maybe our elected officials will stop giving in to the "minority opinions" and begin, once again, to represent the "majority" of ALL of the American people.
SO BE IT............
LETTER FROM THE BOSS......
As the CEO of this organization, I have resigned myself to the fact that
Barrack Obama is our President and that our taxes and government fees will
increase in a BIG way. To compensate for these increases, our prices would
have to increase by about 10%.
But since we cannot increase our prices right now due to the dismal state of
the economy, we will have to lay off six of our employees instead. This has
really been bothering me, since I believe we are family here and I didn't
know how to choose who would have to go.
So, this is what I did. I walked through our parking lot and found six
'Obama' bumper stickers on our employees' cars and have decided these folks
will be the ones to let go. I can't think of a more fair way to approach
this problem. They voted for change, I gave it to them.
I will see the rest of you at the annual company picnic.
I listened to the entire call and: Yes it Was!
You should have tried stable, performance and dividend companies. Companies that have increased their dividends for 50+ years. Stable and the best of the best companies instead of pennies.
Companies like Bank of America, Bears and Sterns, Citi Group and the like!
Sorry for your loss.
No, sorry.
Note to all: Dragon Man passed away in the middle of Feb. He was in his 60's and had been very sick for a long while.
If you wish, I will send any notes to his wife.
Top Hat
Note to all: Dragon Man passed away in the middle of Feb. He was in his 60's and had been very sick for a long while.
If you wish, I will send any notes to his wife.
Top Hat
Note to all: Dragon Man passed away in the middle of Feb. He was in his 60's and had been very sick for a long while.
If you wish, I will send any notes to his wife.
Top Hat
Note to all: Dragon Man passed away in the middle of Feb. He was in his 60's and had been very sick for a long while.
If you wish, I will send any notes to his wife.
Top Hat
Note to all: Dragon Man passed away in the middle of Feb. He was in his 60's and had been very sick for a long while.
If you wish, I will send any notes to his wife.
Top Hat
Note to all: Dragon Man passed away in the middle of Feb. He was in his 60's and had been very sick for a long while.
If you wish, I will send any notes to his wife.
Top Hat
Note to all: Dragon Man passed away in the middle of Feb. He was in his 60's and had been very sick for a long while.
If you wish, I will send any notes to his wife.
Top Hat
My wife accuses me of still being 9! (I'm technically going on 53.)
Winter Fun
The beat goes on and on...................
1. The American people elect a black president with a total of 142 days experience as a US Senator from the most politically corrupt state in America whose governor is ousted from office. The President's first official act is to order the close of Gitmo and make sure terrorists civil rights are not violated.
2. The U.S. Congress rushes to confirm a black Attorney General, Eric Holder, whose law firm we later find out represents seventeen Gitmo Terrorists.
3. The CIA Boss appointee, Leon Panetta has absolutely no experience, has a daughter Linda we find out, who is a true radical anti-American activist and a supporter of all the Anti-American regimes in the western hemisphere.
4. We got the most corrupt female in America as Secretary of State; bought and paid for.
5. We got a Tax Cheat for Treasury Secretary who files his own taxes.
6. A Commerce Secretary nominee who withdrew due to corruption charges.
7. A Tax cheat nominee for Chief Performance Officer who withdrew under charges.
8. A Labor Sec'y nominee who withdrew under charges of unethical conduct.
9. A Sec'y HHS nominee who withdrew under charges of cheating on his taxes.
10. Multiple appointments of former lobbyists after an absolute campaign statement that no lobbyists would be appointed.
11. Without press coverage, Barrack signs bills promoting abortion overseas, and requiring Union labor for Federal Contracts in the Pork Spending bill.
12. Politics of Hope changed to fear and threat. Hope is now re-definied.
And that's just the first three weeks. . . But who's counting?
America is being run by the modern-day Three Stooges ~ Barrack, Nancy, and Harry ~ and they are still trying to define stimulus..."it's spending"...
The congress passes the $800,000,000,000 (that's $800 billion) pork loaded spending bill where the government gives you a smidgen of your tax dollars ($13 per week) making you feel so good about yourself [stimulated] that you want to run out to Wal-Mart and buy a new Chinese-made HDTV and go home and watch Telemundo!
Maybe in the next 3 weeks they can achieve:
- Universal Health Care
- Take away the secret ballot for unions
- Pass the Ban on "conservative talk-radio bill"
- Pass bills paying the mortgages of those who never should have had one in the first place
- Ban all whites from racial discussions of any kind
- Prosecute Bush and Cheyney for so called "war crimes"
- Destroy the capitalistic stock market, an evil product of corporations
- Turn the Gitmo prisioners loose here in our country so as not to violate their rights
- Make it illegal to own a gun without an insurance policy
Yee-haw!!! Only in America, what a country...
An update announcement is due in late March.
The recent activity was due to a Stansberry newletter recommendation.
Closely Linked
CASE STUDY #1: A unique deal with Siegfried helps Arena Pharmaceuticals advance its first product
Ann Thayer
NO MILESTONE is more critical for an emerging pharmaceutical company than launching its first product. And although the drug developer may do the heavy lifting throughout R&D and clinical trials, it often turns to a custom manufacturer to make the product at commercial scale. Whether the developer-manufacturer relationship is simply contractual or a close partnership depends on the companies and their shared history.
San Diego-based Arena Pharmaceuticals is moving toward launching its initial product. Lorcaserin, a small-molecule antiobesity drug, is in Phase III trials scheduled to end next year. "Things are looking promising," Chief Executive Officer Jack Lief says. Following closely behind lorcaserin in Arena's pipeline are four other development programs, including one each with Ortho-McNeil Pharmaceutical and Merck & Co.
SIEGFRiED
FINISHED FORM Arena Pharmaceuticals has bought a facility from Siegfried for making drug tablets."We are fortunate to have a technology that allows us to discover many promising compounds that specifically target G protein-coupled receptors," Lief says. Arena's GPCR-based discovery technology was developed by its chief scientific officer, Dominic P. Behan, who founded Arena with Lief in 1997. Since then, Lief has been advancing Arena's business strategy.
Arena had considered outsourcing much of its drug manufacturing, but fortuitous timing led to a mutually beneficial deal with one of its active pharmaceutical ingredient (API) suppliers. Now, unlike many start-ups for which production and marketing may be an afterthought or left to a larger pharmaceutical partner, "we have plans to manufacture, and at some point I would also like to see Arena develop its own commercialization capabilities," Lief remarks. "As a company grows, its needs change and our thinking has been to expand our capabilities and take on more and more responsibilities that pharmaceutical companies typically assume."
In late 2007, Arena purchased from Siegfried a facility in Zofingen, Switzerland, that makes drug tablets and other finished dosage forms. The price was about $28 million in cash and 1.5 million shares of Arena stock, worth about $12 million at the time. The Swiss custom manufacturer will become a long-term supplier of bulk lorcaserin and is also developing two other Arena APIs. In turn, Arena will manufacture several finished products for Siegfried for at least three years.
"The initial requirement for an arrangement of this nature is that there be a basis of trust," Siegfried CEO Douglas C. Günthardt says. "It's not just a transaction where everybody goes off their own way but really a long-term partnership." The two companies have worked together for about five years with Siegfried in the role of supplier; now Siegfried is also a customer, and Arena is the most important third-party supplier of its generics division, Günthardt adds.
For Siegfried, the transition is eased by the fact that 70 of its employees will move to Arena and continue to run the finished products facility. Siegfried also will supply quality assurance and other services. The facility has been inspected and approved by both the U.S. Food & Drug Administration and Swiss regulators.
DEALS LIKE THIS happen, Günthardt says, "because senior management is in contact and you realize how the other company is evolving and what they are trying to accomplish." The trigger, he adds, can be when companies are nearing the launch of a new product. Arena was at the point of deciding how to handle its manufacturing requirements, which could be substantial for an antiobesity drug. Siegfried, meanwhile, had recently opened a facility in Malta and could move products there to free up capacity in Zofingen.
Now that it's a manufacturer, Arena is faced with the unenviable challenge of forecasting its production-capacity needs, a volume that could vary widely depending on when and whether lorcaserin will be approved and how well it does. The deal includes a 15-year supply agreement for the API—Arena will have other suppliers as well—but the company is in charge of its own tablet-stage production. The Swiss government gave Arena certain tax benefits for its purchase of the facility.
Balancing its ownership risk, Arena gets a turnkey facility with trained staff and an existing slate of products. "The cost of the agreement with Siegfried is about comparable to what outsourcing would cost us between now and the time that we would begin selling our product," Lief explains. "It also makes so much sense for us because we have multiple drugs in development and eventually we'll need them to be manufactured."
Lief anticipates that having production capabilities may facilitate plans to commercialize lorcaserin with a partner because there will be no need to transfer and validate manufacturing processes. "We'll completely avoid that step by supplying our partner with finished product, which also makes for a much more enhanced regulatory approval process," he adds.
Thanks to reduced manufacturing costs, Arena estimates that the facility's purchase price could be recouped within about a year of launching lorcaserin. It is paying Siegfried about two-thirds of the cash upfront and the rest in installments in the third, fourth, and fifth years after closing. Siegfried, meanwhile, cannot sell its Arena shares for three years.
The CEOs structured the deal in a way that connects the interests of their companies. "We care longer term that Arena is successful, and we are aligned with looking out for them," Günthardt says. "Obviously for us it would be very nice if they do have a drug that gets to market because the upside for the shares could be significant.
"And if their lead compound fails, we also suffer because their share price will take a hit," he acknowledges. "That's the nature of the industry, but they also have other products in the pipeline that might come along within two to three years." He points out that the companies complement each other in their expertise and capabilities and that Arena has shifted from an R&D-focused firm into an integrated operation overnight.
This is not the first time that Siegfried has tailored a deal for a pharmaceutical partner. In 2006, it set up a long-term agreement with Celgene, a New Jersey-based company that it had known for about nine years. The deal revolved around Celgene's second drug, the multiple myeloma treatment Revlimid, which was gaining in sales through approvals in more markets and additional uses.
OVER TIME, Celgene will pay Siegfried about $46 million for production capacity in Zofingen that equals roughly 5% of the Swiss firm's total capacity. Because Revlimid is an analog of the human teratogen thalidomide, the U.S. company wanted to maintain control of drug production by conducting the final steps itself. Siegfried provides intermediates, testing, and support services.
As the companies worked together over the past decade, Celgene launched two major drugs and its product sales grew to $1.3 billion in 2007. Günthardt views Arena, like Celgene, as another promising company on which Siegfried is willing to place a bet.
"There are not many small companies that have the vision or ambition of wanting to be an independent pharmaceutical company," Günthardt remarks about its partners. "But Celgene's management pulled it off, and now Jack Lief has plans that are being executed systematically with that in mind."
Not only was Siegfried's management and board of directors impressed enough to want to partner with Arena, but Günthardt believes his former employees have been impressed as well. A few weeks ago, Lief came to visit them at the finished-dosage facility. "Arena has always said it cares about its people, but when the CEO gets on an airplane and comes out here just to meet them and then go back, they were delighted," he explains. "They may have been a bit cynical about what Americans might say and do, but I think they felt that this guy is basically walking the talk.
"It's another reason we feel good that we have done this deal," Günthardt adds. "We care about the people we have here because they have been good employees and we want to make sure they feel comfortable as well. So we are very pleased with how it has worked out so far."
http://pubs.acs.org/cen/coverstory/86/8610cover1.html
Lorcaserin Hydrochloride for Obesity
Lorcaserin hydrochloride, our most advanced drug candidate, is a promising investigative oral treatment for obesity. In September 2006, we initiated a Phase 3 clinical trial program to evaluate the safety and efficacy of lorcaserin for the treatment of obesity. BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management) was the first of three Phase 3 clinical trials in the lorcaserin program. In December 2007, we initiated BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management) and BLOOM-DM (Behavioral modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus), the second and third Phase 3 clinical trials evaluating lorcaserin's safety and efficacy.
In March 2008 an independent Echocardiographic Safety Monitoring Board, or ESMB, performed a planned detailed review of unblinded echocardiographic data of patients in the BLOOM trial 12 months after enrollment of the last patient. The ESMB's review confirmed that differences, if any, in the Month 12 rates of FDA-defined valvulopathy in patients in the lorcaserin and control groups did not meet their predetermined stopping criteria. Based on the ESMB's review, we have continued the Phase 3 program and have been able to confirm that the statistical power calculations used in the design of the Phase 3 program to monitor patients for increased risk of developing valvulopathy are justified. The findings from the Month 12 review build on the ESMB's September 2007 review that evaluated Month 6 echocardiographic data.
We believe lorcaserin selectively stimulates the 5-HT2C serotonin receptor, a GPCR located in the hypothalamus. Stimulation of this hypothalamic receptor is strongly associated with feeding behavior and satiety. We conducted preclinical studies examining the activity and 5-HT receptor subtype specificity of lorcaserin. In these studies, lorcaserin demonstrated a high affinity and selectivity for the 5-HT2C receptor, with approximately 15-fold and 100-fold selectivity in vitro over the human 5-HT2A and 5-HT2B receptors, respectively, and no pharmacologic activity at other serotonin receptors except at concentrations greatly exceeding the expected therapeutic range.
By preferentially targeting the 5-HT2C receptor, we believe we can help patients effectively lose weight in a safe, well tolerated and efficacious manner. Data from Phase 2 clinical trials of lorcaserin demonstrated that patients who received the drug experienced significantly greater weight loss than patients who received placebo. Lorcaserin has been generally well tolerated at all doses investigated in clinical trials dosing patients up to 12 weeks.
Obesity affects tens of millions of adults and children in the United States and poses serious long-term threats to their health and welfare. Studies have shown that modest weight loss of as little as 5% of initial body weight can result in a meaningful reduction in the risks associated with obesity, such as diabetes. Currently, pharmaceutical treatment options for obesity are limited.
(This page was last updated: August 14, 2008. Additional information regarding Arena is available in its SEC filings.)
http://www.arenapharm.com/wt/page/lho.html
Drugs of the Future
Drugs Fut 2007, 32(9): 766
ISSN 0377-8282
Copyright 2007 Prous Science
CCC: 0377-8282
Lorcaserin hydrochloride
Wang, Y., Serradell, N., Bolos, J.
Obesity affects millions of people worldwide and the socio-economic cost of the condition is substantial. Despite lifestyle changes, pharmacotherapy is needed for the treatment of obesity. Lorcaserin is a highly selective 5-HT2C receptor agonist developed for the treatment of obesity. In rats, lorcaserin led to dose-dependent weight loss. Lorcaserin proved safe and well tolerated in healthy volunteers and obese patients. In a phase II clinical study, patients administered 20 mg/day lorcaserin achieved an average weight loss of 3.6 kg (7.9 lbs), which was significantly greater than the average weight loss of 0.3 kg (0.7 lbs) in the placebo group. A phase III clinical trial is ongoing to evaluate the long-term safety and efficacy of lorcaserin in patients with obesity.
http://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=1135518&p_IsPs=N
It's been a while coming, but early indications are they might have a winner.
The chart sure is going wild.
The alligators down in Florida can't wait till the thaw!